Streetbeat News

Stock Prices

HSIC

Henry Schein shares are trading lower after the company reported mixed Q2 financial results and issued FY24 adjusted EPS guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:51 am

PTGX

Protagonist Therapeutics shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:50 am

GBTG

Global Business Travel (GBTG) reported its Q2 2024 financial results, with GAAP EPS of $0.06 beating the estimate of $(0.08), but sales of $625 million missing the estimate of $628.847 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:49 am

JOBY

Joby Aviation shares are trading higher after the company announced it has formally applied for its revolutionary aircraft to be certified for use in Australia.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:49 am

SNSE

Sensei Biotherapeutics reported having $52.3 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This funding is expected to support operations into the fourth quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:48 am

ALIT

Alight reported Q2 adjusted EPS of $0.05, missing the $0.11 estimate. Sales were $538.00M, falling short of the $801.03M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:47 am

VMC

Vulcan Materials (NYSE:VMC) reported Q2 2024 earnings of $2.35 per share, missing the analyst estimate of $2.48. Sales were $2.014 billion, also below the $2.030 billion estimate. Despite the misses, EPS increased by 2.62% year-over-year, while sales decreased by 4.69%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:46 am

HRMY

Harmony Biosciences (NASDAQ:HRMY) reported Q2 2024 adjusted EPS of $1.05, significantly beating the $(0.06) estimate, and a 38.16% increase from last year. However, sales of $172.814M slightly missed the $173.098M estimate, though they were up 28.76% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:46 am

TGTX

TG Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 Briumvi U.S. net product revenue. The company also entered into a term loan facility with Blue Owl Capital.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:45 am

NERV

Minerva Neurosciences reported a Q2 2024 GAAP EPS of $(1.09), missing the estimate of $(0.73). The company had approximately $31M in cash, cash equivalents, and restricted cash as of June 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:43 am